Doctors have long repurposed Roche's Avastin for the eye in place of using the company's pricier Lucentis to save money. Now, a study says the U.S. could save almost $3 billion a year if Medicare patients received the cheaper drug--a prospect Roche isn't so keen on.
Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug.
When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine...
First it was Italy, then it was France, and now the European Union is stepping up to take a serious look at how Swiss drugmakers Roche and Novartis have handled the marketing of their eye drug Lucentis.
The FDA more than a year ago warned cancer docs that it had discovered a counterfeit of Roche's Avastin being shipped from a supplier in New York. Now authorities have come down hard on the owners of the company, indicting them on 73 counts for selling more than $17 million worth of fake or unapproved drugs.
The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.
It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.
Itlaian prosecutors have zeroed in on four executives at Roche and Novartis in their probe of potential fraud in the companies' eye-drug sales, Reuters reports, citing sources. The four executives weren't identified.
Efforts to steer doctors away from off-label use of cancer drug Avastin in favor of the pricier Lucentis for treating sight issues have gotten Swiss drugmakers Roche and Novartis fined by the anticompetition authority in Italy, where prosecutors are also taking a look, and now French regulators say they are in the midst of a probe of their own.
After their antitrust-fighting colleagues levied $251 million in fines against Swiss drugmakers Roche and Novartis on allegations that they colluded to protect sales of their eye drug, Italian prosecutors are now investigating possible market manipulation and fraud, according to Reuters.